Dytrych V, Kuchar J, Ambroz D, Kunstyr J, Grus T, Lindner J, Linhart A, Jansa P
Bratisl Lek Listy. 2020;121(5):356-361. doi: 10.4149/BLL_2020_057.
To compare clinical parameters and quality of life in patients with pulmonary arterial hypertension (PAH) at the time of diagnosis, at the time of LenusPro pump implantation and during intravenous treptostinil treatment.
Seven patients with severe PAH treated with intravenous treptostinil via implantable LenusPro pumps were evaluated, including NYHA classification, six‑minute walking test, BNP and quality of life assessment using the EQ-5D-5L questionnaire before and after pump implantation.
No significant changes were observed in NYHA class and six‑minute walking distance test. There was however a significant improvement in the quality of life and a decrease in BNP levels. The mean EQ-5D-5L index assessed during subcutaneous treptostinil treatment was significantly worse when compared to that assessed during its intravenous application (0.39 ± 0.24 vs 0.78 ± 0.28, p ˂ 0.05); the same is true about the pain/discomfort dimension. Complications occurred, namely one nonfatal pneumothorax, one nonfatal hemothorax, and one event of nonfatal treptostinil intoxication after refilling.
In patients who do not tolerate subcutaneous treptostinil treatment, the use of the LenusPro implantable pump results in a significant improvement in quality of life with an acceptable safety profile (Tab. 2, Fig. 2, Ref. 19).
比较肺动脉高压（PAH）患者在诊断时、植入LenusPro泵时以及静脉注射曲前列尼尔治疗期间的临床参数和生活质量。
对7例通过植入式LenusPro泵静脉注射曲前列尼尔治疗的重度PAH患者进行评估，包括纽约心脏协会（NYHA）分级、六分钟步行试验、脑钠肽（BNP）以及使用EQ-5D-5L问卷在泵植入前后进行生活质量评估。
NYHA分级和六分钟步行距离试验未观察到显著变化。然而，生活质量有显著改善，BNP水平下降。皮下注射曲前列尼尔治疗期间评估的平均EQ-5D-5L指数与静脉应用期间评估的指数相比显著更差（0.39±0.24对0.78±0.28，p＜0.05）；疼痛/不适维度也是如此。发生了并发症，即1例非致命性气胸、1例非致命性血胸以及1例再填充后非致命性曲前列尼尔中毒事件。
在不能耐受皮下曲前列尼尔治疗的患者中，使用LenusPro植入式泵可显著改善生活质量，且安全性可接受（表2，图2，参考文献19）。
